Welcome to: Rimonabant Information Source (rimonabant and fda)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Acomplia rimonabant is a CB-1 (cannabino? N) receptor blocker. It blocks the receptor from acting on the nervous system. The introduction of the drug fools the stomach to believe that it is full. And as a full stomach seems the urge to eat. This drug can also have an impact on the working? Neration of smoking and may be effective in some metabolic disorders and cardiovascular diseases. As rimonabant Acomplia is a newly launched weight loss diet pills, their availability in local stores is scarce and expensive. Buying the online weight loss pill is a good option. One can be sure many discounts for the purchase of the product through the online channel. A person can order Acomplia online and buying the comfort of his or her home forever. It is a sensational product to be imported in several European countries such as weight loss pill.

Rimonabant Pricelist

Please wait while we load the price list
RIO-Europe is a seven-nation study involving patients with a mean body mass index of 36 kg/[m.sup. 2] and an average waist circumference of 110 cm. As is typical of obesity clinical trials, 80% were women. Participants were encouraged by dietitians and counselors to modify their lifestyle by increasing physical activity and adopting a diet with a 600-cal/day deficit. One-fifth of subjects were randomized to placebo, while the remainder received either 5 mg or 20 mg of rimonabant daily. The placebo response was high, which Dr. Van Gaal attributed to the counselors' dedication. Thirty-one percent of patients who completed 1 year of placebo therapy lost more than 5% of their initial body weight, and although that's an impressive figure, it is well below those of the rimonabant groups: 44% in the patients receiving 5 mg/day and a 67% rate in those receiving 20 mg/day.

S.and European regulators are expected to act on Sanofi-Aventis' application to bring the drug to market. In this trial, researchers compared weight-loss, improvements in metabolic variables, and reduction in cardiovascular risk factors for obese diabetics who took Acomplia compared to those on a placebo. Announcement of the results of the RIO-Diabetes trial is slated for a symposium on "Late-Breaking Clinical Trials" set for 2 p.m. PDT June 12th. Researchers have hinted privately to reporters that the results are consistent with the highly encouraging results from their three studies reported earlier -- RIO-North America, RIO-Europe and RIO-Lipids. The fact that the results are being presented at the highest-profile symposium at the American Diabetes Association meeting -- only weeks after Sanofi filed for approval of the drug with the U.